Member Profile

Founded in 1982, Orient EuroPharma Co., Ltd (OEP) was officially listed in the Taipei Exchange in 2003. (Stock code: 4120) Business include pharmaceuticals, oncology drugs, dermo-cosmetics, infant & adult nutrition and healthcare products. OEP also owns two pharmaceutical factories: US FDA inspected oral dosage manufacturing and sterile/cytotoxic injectable manufacturing. Including the R&D site in US, OEP is a multinational pharmaceutical company with core capabilities of integrating drug research and development, clinical trials, manufacturing and drug sales channels. OEP has started to establish oversea subsidiaries since 1993 and keep strengthening marketing and sales capability in the Asian Pacific region. Currently, overseas employees account for more than 40%. OEP collaborates with New Zealand’s Dairy Goat Co-operatives (DGC) to market “Karihome,” a new brand for infant nutrition has successfully entered the Mainland China and Southeast Asia market which makes OEP is one of the few Taiwanese companies able to manage an international brand. Towards on the unique and niche market, the R&D and business strategy of OEP is focusing on developing 505(b)(2) new drugs. In order to driven growth of business continuously, OEP developed technology platforms with patent to expand the competency of R&D and collaborate with globalized company by strategic alliance to accelerate new products on market. Upholding the core value, “Through Integrity, United We Achieve and Be Remarkable,” OEP will pursuit the sustainable development and accomplishment of a benchmarking enterprise in Asia-pacific.